[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jeffrey Statland\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100571518",false,"NCT06721299","Clenbuterol to Target DUX4 in FSHD","Clenbuterol to Target DUX4 in FSHD (Target FSHD): Open Label Safety and Tolerability Study of 3 Doses of Clenbuterol","Target FSHD","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of FSHD type 1 or 2, or have a clinical diagnosis of FSHD type 1 with a first degree relative with confirmed mutation\n* between 18 and 75 years of age\n* with a clinical severity score between 0 and 10\n* Able to walk 30ft without support of another person\n* Showing anti-gravity strength on at least one of the tibialis anterior muscles or having an MRI eligible muscle in the leg for needle biopsy\n* willing and able to provide informed consent\n* agree to follow the contraceptive requirement for duration of the study\n\nExclusion Criteria:\n\n* Pregnant or planning to become pregnant during the conduct of the study\n* have a poorly controlled medical condition\n* Were involved in a study of an experimental agent within 3 months of enrollment\n* Are taking beta-blockers or anabolic agent or potassium wasting diuretics\n* Are taking or are planning to take a GLP-1 Agonist during trial\n* have any condition or contraindication which would interfere with testing or preclude use of beta-agonist\n* Are taking blood thinners or medications which make a needle muscle biopsy contra-indicated\n* Has contraindication to lactose such as galactosmia, lactase deficiency and glucose-galactose malabsorption. For those who are lactose intolerant, the PI will determine acceptability based on tolerance reaction to lactose\n* Are taking any medications or therapies with a contraindication to Clenbuterol","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.",[27],"Muscular Dystrophy, Facioscapulohumeral",[29],"FSHD","RECRUITING","2026-02-24",{"date":33,"type":34},"2026-02-25","ACTUAL",{"date":36,"type":34},"2025-06-25",{"date":38,"type":21},"2028-07",{"name":40,"class":41},"Jeffrey Statland","OTHER",3,""]